Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on December 3, 2019. The registrant is a Delaware corporation trading on the Nasdaq Global Market under the symbol AGLE. The filing primarily serves to disclose upcoming corporate communications and clinical trial updates scheduled for the Evercore ISI 2nd Annual HealthCONx Conference in Boston, Massachusetts.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. As a Form 8-K focused on regulatory disclosure and event announcements, specific financial metrics are not reported herein. Investors should refer to the Company's most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, for financial details.
Material Changes and Program Updates
The filing announces material updates regarding the Company's clinical development programs:
- AEB4104 Program: The Company will announce the design of its Phase 1/2 clinical trial for patients with homocystinuria. Key endpoints include reductions in plasma total homocysteine levels, pharmacokinetics, and safety/tolerability.
- AEB5100 Program: The Company expects to provide dose response data in the first quarter of 2020.
Guidance, Outlook, and Risks
Timeline Outlook:
- Q1 2020: Expected filing of a Clinical Trial Application (CTA) for AEB4104 and provision of dose response data for AEB5100.
- Q2 2020: Expected initiation of the Phase 1/2 trial for AEB4104.
- Q1 2021: Expected provision of initial clinical data for AEB4104.
Risks and Contingencies: The report contains forward-looking statements subject to risks and uncertainties, including cash forecasts, clinical trial timing and success, regulatory submissions, patient enrollment capabilities, and collaboration outcomes. The Company explicitly states it undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Spyre Therapeutics) and the filing registrant (Aeglea BioTherapeutics).
- Review the attached Exhibit 99.1 (Corporate Presentation) for detailed trial design specifics not fully elaborated in the text.
- Consult the Form 10-Q for the quarter ended September 30, 2019, to assess current cash runway and liquidity status.
- Monitor the Company's website (www.aegleabio.com) for the posted presentation and any subsequent updates on trial initiation.